Biliary Tract Cancer: A Molecular Challenge
A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Cancer Biology and Oncology".
Deadline for manuscript submissions: closed (31 March 2022) | Viewed by 2314
Special Issue Editor
Special Issue Information
Dear Colleague,
Biliary tract cancers are cancers with a very poor prognosis. Current treatments are not very effective.
These cancers are among those with the most molecular abnormalities, some of which are targetable, such as HDI1 mutations and FGFR fusion abnormalities. Research in this cancer naturally focuses on the development of treatments targeting these abnormalities.
Another promising therapeutic development path is immunotherapy with already many clinical trials underway.
Cancers of the intrahepatic bile ducts, extrahepatic bile duct and gallbladder have different molecular characteristics, different prognosis and different responses to treatments.
Improving the management of these cancers will necessarily require a better knowledge of molecular abnormalities and the development of targeted therapies.
These cancers being rare an international collaboration is necessary to quickly improve their management.
Dr. Sylvain Manfredi
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- rare cancers
- tumor molecular analysis
- targeted therapy
- immunotherapy
- basket trial
- umbrella trial
- international collaboration
